Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
47.12
87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Total Current Liabilities
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Current Liabilities
¥2.7B
|
CAGR 3-Years
48%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Current Liabilities
¥12.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Total Current Liabilities
¥1.4B
|
CAGR 3-Years
100%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Current Liabilities
¥1.6B
|
CAGR 3-Years
27%
|
CAGR 5-Years
41%
|
CAGR 10-Years
32%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Current Liabilities
¥22.7B
|
CAGR 3-Years
32%
|
CAGR 5-Years
39%
|
CAGR 10-Years
68%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Current Liabilities
¥297.7m
|
CAGR 3-Years
49%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. has emerged as a key player in the Chinese biopharmaceutical landscape, combining innovation with a commitment to improving healthcare outcomes. Founded in 1990, the company specializes in the research, development, manufacturing, and sale of a wide range of vaccines, diagnostic reagents, and biologic drugs. As one of the forefront companies in China's biotech sector, Wantai has leveraged its technological expertise to create products that address significant public health needs, such as viral infections and autoimmune diseases. With a robust pipeline and strong government support, the company positions itself as a critical contributor to the nation's healthcare ecosystem while aligning with global trends in biopharmaceutical development. For investors, Wantai represents an attractive opportunity, particularly as the demand for effective vaccines and diagnostics continues to surge worldwide. The company's recent IPO and strategic partnerships have bolstered its financial standing, providing a solid foundation for future growth. With an expanding portfolio that includes COVID-19 vaccines and innovative therapeutics, Wantai is poised to capitalize on the growing emphasis on preventative medicine and public health. Moreover, the company's commitment to quality and extensive research capabilities create a sustainable competitive advantage that could yield promising returns for investors navigating the evolving biotechnology market.
See Also
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Current Liabilities?
Total Current Liabilities
2.7B
CNY
Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Current Liabilities amounts to 2.7B CNY.
What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
51%
Over the last year, the Total Current Liabilities growth was -23%. The average annual Total Current Liabilities growth rates for Beijing Wantai Biological Pharmacy Enterprise Co Ltd have been 48% over the past three years , 51% over the past five years .
You don't have any saved screeners yet
